Distribution of serious and nonserious adverse events days 1–3 or 4 weeks after intrathecal gadobutrol, independent of dose (n = 196)a
| iNPH Cohort | Non-iNPH Cohort | |||
|---|---|---|---|---|
| Days 1–3 | 4 Weeks | Days 1–3 | 4 Weeks | |
| Serious adverse events | ||||
| Present (No.) | 0 | 0 | 0 | 0 |
| Absent (No.) (%) | 144 (100%) | 134 (100%) | 52 (100%) | 49 (100%) |
| Nonserious adverse events | ||||
| Present (No.) (%) | 47 (32.6%) | 6 (4.5%) | 30 (57.7%) | 3 (6.1%) |
| Absent (No.) (%) | 97 (67.4%) | 128 (95.5%) | 22 (42.3%) | 46 (93.9%) |
| Missing data (No.) | 0 | 10 | 0 | 3 |
a Data are presented as number of individuals (percentage are in parentheses). Comparison of the distribution of nonserious adverse events between the iNPH and non-iNPH cohorts after days 1–3 (Pearson χ2, P = .002) and 4 weeks (Pearson χ2, P = .649).